Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Usability of FOL100 Lotion vs Oral Finasteride in Androgenetic Alopecia
NCT05611593Phase 1Recruiting
- Sponsor
- Follicle Pharma
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of FOL-100 in androgenetic alopecia (AGA) (2 arms), sponsored by Follicle Pharma. Primary endpoint: Incidence rate of Adverse Events and Serious Adverse Events at 28 weeks. Started Oct 2022; status: recruiting.
02
Drugs
FOL-100
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05611593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611593.